Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-06-27
2006-06-27
Russel, Jeffrey Edwin (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S014800, C514S015800, C514S016700, C514S017400, C514S018700, C514S019300, C514S423000
Reexamination Certificate
active
07067489
ABSTRACT:
Methods and products for stimulating hematopoiesis, preventing low levels of hematopoietic cells and producing increased numbers of hematopoietic and mature blood cells are provided. The methods and products can be used both in vivo and in vitro. The methods involve administering an agent of Formula Iwherein m is an integer between 0 and 10, inclusive; A and A1are L-amino acid residues such that the A in each repeating bracketed unit can be the same or a different amino acid residue; the C bonded to B is in the L-configuration; the bonds between A and N, A1and C, and between A1and N are peptide bonds; and each X1and X2is, independently, a hydroxyl group or a group capable of being hydrolyzed to a hydroxyl group in aqueous solution at physiological pH. The products include kits comprising the agent of Formula I.
REFERENCES:
patent: 4318904 (1982-03-01), Shaw et al.
patent: 4443609 (1984-04-01), Oude Alink et al.
patent: 4499082 (1985-02-01), Shenvi et al.
patent: 4582821 (1986-04-01), Kettner et al.
patent: 4636492 (1987-01-01), Kettner et al.
patent: 4644055 (1987-02-01), Kettner et al.
patent: 4652552 (1987-03-01), Kettner et al.
patent: 4664262 (1987-05-01), White
patent: 4935493 (1990-06-01), Bachovchin et al.
patent: 4963655 (1990-10-01), Kinder et al.
patent: 5093477 (1992-03-01), Mölling et al.
patent: 5187157 (1993-02-01), Kettner et al.
patent: 5215926 (1993-06-01), Etchells, III et al.
patent: 5242904 (1993-09-01), Kettner et al.
patent: 5250720 (1993-10-01), Kettner et al.
patent: 5288707 (1994-02-01), Metternich
patent: 5296604 (1994-03-01), Hanko et al.
patent: 5329028 (1994-07-01), Ashkenazi et al.
patent: 5378624 (1995-01-01), Berenson et al.
patent: 5384410 (1995-01-01), Kettner
patent: 5444049 (1995-08-01), de Nanteuil et al.
patent: 5462928 (1995-10-01), Bachovchin et al.
patent: 5489025 (1996-02-01), Romick
patent: 5506130 (1996-04-01), Peterson et al.
patent: 5527923 (1996-06-01), Klingler et al.
patent: 5543396 (1996-08-01), Powers et al.
patent: 5554728 (1996-09-01), Basava et al.
patent: 5635386 (1997-06-01), Palsson et al.
patent: 5635387 (1997-06-01), Fei et al.
patent: 5646043 (1997-07-01), Emerson et al.
patent: 5965532 (1999-10-01), Bachovchin
patent: 6040145 (2000-03-01), Huber et al.
patent: 6100234 (2000-08-01), Huber et al.
patent: 6258597 (2001-07-01), Bachovchin et al.
patent: 6300314 (2001-10-01), Wallner et al.
patent: 6355617 (2002-03-01), Luke et al.
patent: 6503882 (2003-01-01), Huber et al.
patent: 6692753 (2004-02-01), Huber et al.
patent: 6770628 (2004-08-01), Wallner et al.
patent: 6825169 (2004-11-01), Bachovchin et al.
patent: 6875737 (2005-04-01), Bachovchin
patent: 2003/0158114 (2003-08-01), Wallner et al.
patent: 2003/0212044 (2003-11-01), Huber et al.
patent: 2004/0077601 (2004-04-01), Adams et al.
patent: 2004/0152192 (2004-08-01), Bachovchin et al.
patent: 2005/0008644 (2005-01-01), Huber et al.
patent: 158109 (1982-12-01), None
patent: 270382 (1989-07-01), None
patent: 296075 (1991-11-01), None
patent: 0356223 (1990-02-01), None
patent: 0371467 (1990-06-01), None
patent: 0471651 (1992-02-01), None
patent: 0481311 (1992-04-01), None
patent: 0615978 (1994-09-01), None
patent: 0420913 (1995-11-01), None
patent: 0688788 (1995-12-01), None
patent: WO 89/03223 (1989-04-01), None
patent: WO 91/16339 (1991-10-01), None
patent: WO 91/17767 (1991-11-01), None
patent: WO 92/12140 (1992-07-01), None
patent: WO 92/17490 (1992-10-01), None
patent: WO 93/02057 (1993-02-01), None
patent: WO 93/05011 (1993-03-01), None
patent: WO 93/08259 (1993-04-01), None
patent: WO 93/10127 (1993-05-01), None
patent: WO 93/16102 (1993-08-01), None
patent: WO 94/03055 (1994-02-01), None
patent: WO 94/03055 (1994-02-01), None
patent: WO 94/09132 (1994-04-01), None
patent: WO 94/20526 (1994-09-01), None
patent: WO 94/25873 (1994-11-01), None
patent: WO 94/28915 (1994-12-01), None
patent: WO 94/29335 (1994-12-01), None
patent: WO 95/11689 (1995-05-01), None
patent: WO 95/11689 (1995-05-01), None
patent: WO 95/12618 (1995-05-01), None
patent: WO 95/15309 (1995-06-01), None
patent: WO 95/29190 (1995-11-01), None
patent: WO 95/29691 (1995-11-01), None
patent: WO 95/34538 (1995-12-01), None
patent: WO 96/40263 (1996-12-01), None
patent: WO 96/40858 (1996-12-01), None
patent: WO 98/00439 (1998-01-01), None
patent: WO 98/50046 (1998-11-01), None
patent: WO 98/50066 (1998-11-01), None
patent: WO 99/16864 (1999-04-01), None
patent: WO 00/10549 (2000-03-01), None
Colowick, S., et al., “Methods in Enzymology”, pp. 220-225, vol. XLVI, not dated.
Cordes, E., et al., “Transition States For Hydrolysis of Acetals, Ketals Glycosides, and Glycosylamines”, Chapter 11, pp. 429-465, not dated.
Thompson, R., “Use of Peptide Aldehydes to Generate Transition-State Analogs of Elastase”,Biochemistry, (1973), 12:1:47-51.
Baugh, R., et al., “Proteinases and Tumor Invasion”, (1980), 165:157-179.
Bodanszky, M., “Principles of Peptide Synthesis”,Springer-Verlag, (1984), vol. 16.
Bodanszky, M., “The Practice of Peptide Synthesis”,Springer-Verlag, (1984), vol. 21.
Matteson, D., et al., “Synthesis and Properties of Pinanediol □-Amido Boronic Esters”Organometallics, (1984), 3:1284-1288.
Powers, C., et al., “Elastase Inhibitors For Treatment of Emphysema—NHLBI Workshop Summary”,US Dept. of Helath and Human Services, (1985), 1097-1100.
Yoshimoto, T., et al., “Comparison of Inhibitory Effects of Prolinal-Containing Peptide Derivates on Prolyl . . . ”, (1985), 98:975-979.
Kettner, C.A., et al., “Kinetic Properties of the Binding of Alpha-Lytic Protease to Peptide Boronic Acids”,Biochemistry, (1988), 27:7682-7688.
Tam, J.P., “Synthetic Peptide Vaccine Design: Synthesis and Properties of a High-Density Multiple Antigenic Peptide System”, Proc Natl Acad Sci U S A , (1988), 85:5409-5413.
Bailey, P.D., “An Introduction to Pepetide Chemistry”, Wiley Publishers, (1990), 1-81.
Kettner, C.A. and Shenvi, A.B., “Peptide Boronic Acid Inhibitors of Trypsin-Like Proteases, Their Preparation and Use as Anticoagulants and Inflammation Inhibitors”, Chemical ABSTRACT ONLYs, (1990), 112:80 (91790c).
Bachovchin, W.W., et al., “Inhibition of IGA1 Proteinases FromNeisseria gonorrhoeaeandHemophilus influenzaeby Peptide Prolyl Boronic Acids”, J Biol Chem, (1990), 265: 3738-3743.
Kinder D.H., et al., “Analogues of Carbamyl Aspartate as Inhibitors of Dihydroorotase: Preparation of Boronic Acid Transition-State Analogues and A Zinc Chelator Carbamylhomocysteine, Carbamylhomocysteine”, J Med Chem, (1990), 33:819-823.
Flentke, G.R., et al., “Inhibition of Dipeptidyl Aminopeptidase IV (DP-IV) by XAA-Boropro Dipeptides and Use of These Inhibitors to Examine the Role of DP-IV in T-Cell Function”, Proc Natl Acad Sci U S A, (1991), 88:1556-1559.
Schon, E., et al., “Dipeptidyl Peptidase IV in the Immune System”, Biol Chem Hoppe-Seyler, (1991), 372:305-311.
Kubota, T., et al., “Involvement of Dipeptidyl Peptidase IV in an In Vivo Immune Response”, Clin Exp Immunol, (1992), 89:192-197.
Gutheil, W.G., et al., “Separation of L-Pro-Dl-Boropro Into Its Component Diastereomers and Kinetic Analysis of Their Inhibition of Dipeptidyl Peptidase IV. A New Method For the Analysis of Slow, Tight-Binding Inhibition”, Biochemistry, (1993), 32:8723-8731.
Kelly, T.A., et al., “Immunosuppressive Boronic Acid Dipeptides: Correlation Between Conformation and Activity”,J Am Chem Soc, (1993), 115:12637-12638.
Songyang, Z., et al., “SH2Domains Recognize Specific Phosphopeptide Sequences”,Cell, (1993), 72:767-778.
Subramanyam, M., et al. , “Mechanism of HIV-1 TAT Induced Inhibition of Antigen-Specific T Cell Responsiveness”,J Immunol, (1993), 150:2544-2553.
Demuth, H.U., et al., “Design of (Omega-N-(O-Acyl)Hydroxy Amid) Aminodicarboxylic Acid Pyrrolidides as Potent Inhibitors of Proline-Specific Peptidases”,FEBS Lett, (19
Adams Sharlene
Jones Barry
Miller Glenn T.
Wallner Barbara P.
Point Therapeutics, Inc.
Russel Jeffrey Edwin
Wolf Greenfield & Sacks P.C.
LandOfFree
Hematopoietic stimulation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hematopoietic stimulation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hematopoietic stimulation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3660714